Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare Inc (SRTS) delivers innovative superficial radiation therapy solutions for non-melanoma skin cancers and keloid treatment. This news hub provides investors and medical professionals with essential updates on the company's FDA-cleared devices, clinical advancements, and strategic partnerships.
Access timely updates on treatment protocol developments, technology enhancements, and market expansion initiatives. Our curated news collection features regulatory milestones, peer-reviewed study results, and operational updates directly impacting the dermatology and radiation oncology sectors.
Key focus areas include new device clearances, clinical efficacy data, partnership announcements with healthcare providers, and innovations in non-invasive treatment delivery. All content undergoes rigorous verification to ensure accuracy in reporting medical device developments.
Bookmark this page for consolidated access to SRTS's latest advancements in targeted radiation therapy. Return regularly for verified updates on this pioneering medical technology company's progress in transforming skin condition treatment protocols.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced the publication of a prospective study in the Journal of the American Academy of Dermatology, demonstrating a significantly low recurrence rate of keloids after superficial radiation therapy (SRT) post-excision. The study showed a 6.25% recurrence rate at six months, with no recurrences at 24 months for the follow-up group. The study suggests that a single 8 Gy dose of SRT may effectively reduce keloid recurrence, especially in steroid-resistant cases. This research highlights the growing acceptance of SRT in dermatology.
Sensus Healthcare, Inc. (SRTS) reported Q3 2020 revenues of $1.6 million, a decline from $5.8 million in Q3 2019, attributed mainly to COVID-19 impacts. The net loss was $(1.7) million, or $(0.10) per share, compared to a $(0.7) million loss in the prior year. Despite challenges, the company made strategic moves, such as acquiring mobile laser businesses, and appointed Megan Cornish to its Board. They began generating recurring revenues from Sentinel IT Solutions, and sold two SRT-100™ systems in China, looking to expand further in Asia.
Sensus Healthcare (Nasdaq: SRTS) announced the appointment of Megan Cornish to its board of directors, effective January 1, 2021, increasing the board to six members. Cornish brings over a decade of experience in government relations and lobbying, particularly in food distribution and public policy. The CEO, Joe Sardano, highlighted her potential to enhance the company’s efforts in promoting superficial radiation therapy and expanding awareness among healthcare providers and patients. Cornish aims to leverage her background to improve access to non-invasive treatments for skin cancer.
Sensus Healthcare (Nasdaq: SRTS) will host a conference call on November 5, 2020 at 4:30 p.m. ET to discuss its third quarter financial results and provide a business update on recent and upcoming milestones.
The call is accessible via dial-in numbers and will also be webcast live, with a replay available thereafter. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing innovative technologies such as the Sculptura™ system and SRT-100™.
Sensus Healthcare (Nasdaq: SRTS) announced a retrospective study revealing a keloid recurrence rate of only 10.4% at 12 months for patients treated with superficial radiation therapy (SRT) after keloidectomy, significantly lower than the typical rate of over 80% with surgical excision alone. This study, published in the Journal of Clinical and Aesthetic Dermatology, involved 61 subjects and highlighted SRT's effectiveness, confirming its potential as a game-changer for treating keloids. The Kaplan-Meier survival probability cure rate stood at 85.6% from 24 months post-treatment.
Sensus Healthcare, Inc. (SRTS) reported second quarter results for 2020, revealing revenues of $1.2 million, down from $7.5 million in Q2 2019, largely due to COVID-19 impacts. The company experienced a net loss of $2.6 million, or $0.16 per share, compared to a profit of $0.1 million a year prior. Cash reserves increased to $18.9 million. Recent strategic moves include acquiring two mobile laser companies in Florida, aiming to generate $1 million in base revenues over the next year, and expanding marketing efforts post-pandemic.
Sensus Healthcare (Nasdaq: SRTS) has acquired two mobile aesthetic laser companies, Aesthetic Mobile Laser Services and Aesthetic Laser Partners, significantly expanding its dermatology customer base in Florida. These acquisitions are anticipated to generate an additional $1.0 million in revenue over the next 12 months and are immediately accretive to earnings. The new division, Sensus Laser Aesthetic Solutions, will be led by management from the acquired companies, enhancing market reach and technology integration as Sensus plans to introduce its own aesthetic laser products.
Sensus Healthcare (Nasdaq: SRTS) will hold a conference call on August 6, 2020, at 4:30 p.m. ET to discuss its Q2 2020 financial results and provide a business update, including recent and upcoming milestones. Investors can access the call via dial-in numbers or a live webcast. The company specializes in non-invasive treatments for oncological and non-oncological conditions, highlighting its innovative products like the Sculptura™ system and SRT-100™ series, aimed at improving patient quality of life.
Sensus Healthcare (Nasdaq: SRTS) has announced the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales, focusing on the Southeast Asian market for Superficial Radiation Therapy (SRT) products. Mr. Suen's experience includes nearly 20 years in medical device sales in Asia, contributing to the successful shipment of an SRT-100 system to China. CEO Joe Sardano expressed confidence in Mr. Suen's abilities, highlighting potential growth in shipments of SRT-100 units. Sensus specializes in non-invasive treatment devices targeting oncological conditions.
Sensus Healthcare (Nasdaq: SRTS) announced that CEO Joe Sardano will present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar on July 16, 2020. This event aims to discuss the reopening of medical practices post-COVID-19, exploring revenue recovery, patient engagement, and the adaptation of commercialization strategies. It will include Q&A sessions and panel discussions to share insights and strategies on navigating the changing healthcare landscape. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.
